RapidSOS to Deliver MedicAlert User Information to 999 Systems During Emergencies

C5 Capital

Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure

OCTOBER 29, 2020 – MINNEAPOLIS, MN. Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the completion of a $70 million equity financing. The round was led by new investor Vensana Capital alongside Lightstone Ventures with participation from existing investors Endeavour Vision, New Enterprise Associates, Morgenthaler Ventures and Canaan Partners.

“This oversubscribed financing round is a great vote of confidence in our team, product and mission to change the treatment paradigm for CLBP,” said Art Taylor, President and CEO of Relievant Medsystems. “2020 will be a record year for Relievant and the commercialization of the Intracept Procedure. With the recent publication of our 5-year data showing sustained improvements in pain and function, we expect even greater adoption in 2021 as more and more physicians make Intracept a core part of their CLBP patient care pathway. We are delighted to have such strong financial support to fuel this rapid commercial growth and to make this much-needed treatment available to more patients and physicians.”

Chronic low back pain is a widespread and often severely debilitating condition estimated to affect nearly 30 million people in the U.S., with over 70 percent failing to find adequate relief with conservative care and are not candidates for surgery. Until recently, the intervertebral discs have been thought to be the primary source of pain, referred to as discogenic pain, in most patients with CLBP. Relievant’s Intracept Procedure is a minimally invasive treatment based upon ground-breaking anatomic research that demonstrated many of these patients actually suffer from vertebrogenic pain – pain originating from the vertebral endplates that is transmitted through the basivertebral nerve. The Intracept Procedure is supported by two Level I randomized controlled clinical trials and long-term data demonstrating improvements in pain and function lasting more than 5-years post-procedure. It is estimated that over five million CLBP patients in the U.S. have vertebrogenic pain and are candidates for the Intracept Procedure.

As part of the financing, Justin Klein, MD, JD, Co-Founder and Managing Partner at Vensana Capital, will join Relievant’s board of directors.

“The team at Relievant has created a category-defining medical procedure that truly has the potential to transform the treatment of CLBP,” said Justin Klein. “The Intracept procedure is a safe, patient-friendly treatment that has resonated with physician leaders in the field and has been proven to significantly reduce pain and disability, now beyond five years in well-conducted clinical trials. With the millions of patients in the U.S. suffering from chronic axial low back pain indicated for Relievant’s Intracept Procedure, we believe Intracept is an outstanding example of medical technology innovation and is one that can also positively impact our country’s ongoing opioid epidemic.”

About Relievant Medsystems

Relievant Medsystems is a privately-held medical device company that is transforming the treatment of Chronic Low Back Pain (CLBP) with the Intracept Procedure – a novel, clinically-proven and commercially-available treatment designed to improve the quality of life for the millions of patients suffering from CLBP from degenerative disk disease with Modic changes, a biomarker indicating that their pain is vertebrogenic in origin. Learn more at www.relievant.com.

Contact

Chris Geyen
Relievant Medsystems
(650) 368-1000
investors@relievant.com

Categories: News

Tags:

Nemera boosts parenteral product portfolio and small series capabilities in latest acquisition

Montagu

This acquisition strengthens Nemera’s proprietary product offering and establishes operations footprint in Eastern Europe.

Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.

We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future.

Marc Hämel, CEO of Nemera

Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.

This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters the company’s small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands their overall proprietary product portfolio. Copernicus’s fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large-scale manufacturing capabilities. Furthermore, Copernicus’s marketed reusable pen injectors are of great value from a sustainability standpoint.

With this acquisition Nemera establishs an operations footprint in Eastern Europe. In order to accompany Copernicus’s solid forecasted growth, they will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.

Marc Hämel, CEO of Nemera said, “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.

“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.

Montagu first partnered with Nemera in its 2014 carve-out from Rexam.  Montagu reinvested in the business in 2019 supporting its ambitious organic and acquisitive growth plans.

Categories: News

Tags:

Nemera boosts parenteral product portfolio and small series capabilities in latest acquisition

Montagu

his acquisition strengthens Nemera’s proprietary product offering and establishes operations footprint in Eastern Europe.

Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.

We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future.

Marc Hämel, CEO of Nemera

Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.

This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters the company’s small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands their overall proprietary product portfolio. Copernicus’s fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large-scale manufacturing capabilities. Furthermore, Copernicus’s marketed reusable pen injectors are of great value from a sustainability standpoint.

With this acquisition Nemera establishs an operations footprint in Eastern Europe. In order to accompany Copernicus’s solid forecasted growth, they will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.

Marc Hämel, CEO of Nemera said, “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.

“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.

Montagu first partnered with Nemera in its 2014 carve-out from Rexam.  Montagu reinvested in the business in 2019 supporting its ambitious organic and acquisitive growth plans.

Categories: News

Tags:

Oakley acquires WindStar Medical

Oakley

Oakley Capital (“Oakley”) is pleased to announce that it has agreed to acquire WindStar Medical GmbH (“WindStar Medical”) from ProSiebenSat.1 majority-owned NuCom Group.

WindStar Medical is Germany’s leading over-the-counter (“OTC”) consumer healthcare company. The platform, which is expected to generate over €120 million in revenues this year, designs, develops and commercialises branded consumer health and private label products, with a track record of establishing best-in-class medical formulations and brands.

The Consumer Brands segment of WindStar Medical offers a wide range of premium high-growth branded products in Germany, including SOS (wound care / disinfectants), Zirkulin (gastro-intestinal care), GreenDoc (mental wellbeing) and EyeMedica (eye health). WindStar Medical is also a provider of Private Label products to the leading German drug stores and supermarkets, whilst also developing an international distribution footprint through existing and new partners.

WindStar Medical benefits from the long-term structural growth of Germany’s consumer health market. This growth is being driven both by demographic trends, such as an ageing population, and a shift in consumer preferences driven by factors such as increased awareness of physical and mental wellbeing and willingness to prevent illness. Through its investment, Oakley will support the company’s management team as they continue to drive revenue growth, product innovation, digitalisation, as well as identifying opportunities to scale the business through accretive acquisitions.

The investment in WindStar Medical builds on Oakley’s successful track record of investing in leading consumer platforms in the DACH region, including Verivox, Parship Elite and more recently Wishcard Technologies and 7NXT / Gymondo. The business displays the typical Oakley deal characteristics, as it has an asset-light business model, industry-leading operational capabilities, and an attractive growth profile.

 

“WindStar Medical is a unique OTC platform in a highly attractive space that Oakley is excited to be investing in, having closely followed both the development of the business and management over recent years. We look forward to working together with the team and utilising our broad expertise in digitalisation, go-to-market and M&A to help WindStar Medical accelerate its growth trajectory in Germany and international markets.”
Peter Dubens
Managing Partner of Oakley Capital

Categories: News

Tags:

Avedon expands DELABO.GROUP with acquisitions of Rauschelbach Zahntechnik, Dentaltechnik Knebelsberger and Laufer Zahntechnik

Avedon

Düsseldorf, October 21st, 2020 – DELABO.GROUP, a leading German platform of dental laboratories backed by Avedon Capital Partners, is glad to announce the acquisitions of Rauschelbach Zahntechnik GmbH, Dentaltechnik Knebelsberger GmbH and Laufer Zahntechnik GmbH. The addition of these three independent German dental laboratories with complementary technical and operational capabilities will strengthen the group and firmly establish DELABO.GROUP among the 5 largest players in the German dental laboratory market.

DELABO.GROUP was founded in September 2019 and pursues a buy & build strategy in the fragmented German dental laboratories market. Since foundation, the group already conducted 7 transactions and will likely double in size by the end of 2020 as compared to the initial platform. The group offers a comprehensive portfolio of domestically produced dental prosthetics across all relevant price/quality combinations as well as a wide range of high-end services. Today, the combined group employs more than 230 employees across 8 locations. Investments into technology and the harmonization of production processes, a shared organizational set-up as well as in strategic sales and marketing initiatives are ongoing and are slowly starting to bear fruit.

Thomas Dold, CEO DELABO.GROUP:
“We are very pleased to welcome these three excellent labs to the DELABO.GROUP and thereby further expand our network and our presence in both North- and South-Germany. These acquisitions perfectly fit with our strategy and it will be the beginning of a fruitful partnership. It is great to see that we are able to enthuse such exceptional entrepreneurs like Frank Rauschelbach, Ralf Schieweg and Andreas Laufer with our concept and together, we will accelerate the impressive growth the DELABO.GROUP has achieved thus far. Especially in these uncertain times, this is a strong sign that we are on the right track with our value proposition and our vision.”

About Rauschelbach Zahntechnik GmbH
Rauschelbach Zahntechnik in Pinneberg near Hamburg is an innovative dental laboratory characterized by outstanding expertise in the field of implantology, combination technology and anterior aesthetics. Managing Director Frank Rauschelbach focuses on digitalization in combination with individual craftsmanship as well as a personal exchange with dentists and patients. With this renowned partner laboratory, the DELABO.GROUP strengthens its position in the market and further expands its presence in northern Germany.

About Dentaltechnik Knebelsberger GmbH
Dentaltechnik Knebelsberger is located in Karlsruhe and is headed by Managing Director Ralf Schieweg, who has been working for the company since 1993. With more than 40 employees, Knebelsberger Zahntechnik covers the entire spectrum of modern, digital dental technology. Special expertise includes innovative measuring systems and computer-aided CAD/CAM systems as well as the treatment of functional disorders with the DIR system. The claim of Knebelsberger Zahntechnik is: Quality in all technical and aesthetic aspects as well as strong service and reliability.

About Laufer Zahntechnik GmbH
Laufer Zahntechnik GmbH is located in Mannheim and operates nation-wide and is one of the largest and leading dental laboratories in Germany in the field of implantology and combined dentures. Laufer Zahntechnik was founded in 1989 by master dental technician Andreas Laufer, who is the managing director of the laboratory, now employing around 50 employees. The innovative entrepreneur has always invested in new technologies, which is why Laufer Zahntechnik was, for example, one of the first laboratories in Germany with a high-precision 3D metal printer.

About the DELABO.GROUP
DELABO.GROUP is a buy & build platform in the fragmented German dental laboratories market. The value proposition of the group is based on its comprehensive product offering, which comprises all medically relevant price-quality product combinations as well as a broad range of supportive services for dentists and patients. Despite acting as a nation-wide dental lab platform, the Group emphasizes the regional character of the dental laboratories by leveraging the respective brand heritage as well as the local presence of each group lab. DELABO.GROUP labs are supported in terms of administrative activities, operational investments, recruitment of skilled labor force and the exploration of different growth avenues. Additionally, the Group seeks to extend its geographical coverage as well as its regional presence by pursuing further acquisitions of dental labs in the upcoming years. For more information please visit https://www.delabo.com.

About Avedon Capital Partners
Avedon is a leading growth capital investor based in Amsterdam and Düsseldorf. Avedon invests in small and medium-sized companies in Western Europe with a focus on the software & technology, industrials, consumer & leisure, and business services sectors. Avedon works closely with its management teams to realize growth ambitions and has a long track record of successfully delivering results through autonomous growth and buy-and-build strategies. For more information please visit www.avedoncapital.com.

Categories: News

Tags:

Clearview Re“Capitol”izes Capitol Imaging

Clearview

Stamford, CT, October 21, 2020 — Clearview Capital Fund IV, L.P. and its affiliates (“Fund IV”) announced today the recapitalization, in
partnership with management, of Capitol Imaging Services, LLC (“Capitol Imaging” or the “Company”). The transaction closed on October 1,
2020.

Headquartered in Metairie, LA, Capitol Imaging is a leading provider of outpatient diagnostic
imaging services in Louisiana and Alabama. Through its 20-freestanding facilities, the Company
offers multi-modality capabilities including MRI, CT, and mammography, among others. The
Company was founded by Dr. John Hamide who began acquiring diagnostic imaging centers in
2013. He and the management team have since completed 18 acquisitions, building one of the
largest outpatient imaging platforms in the Gulf South region today.
Through its market leading position, the Company stands to benefit from favorable industry
dynamics expected to drive increases to outpatient imaging volumes as a result of its comparatively
low cost relative to hospital-based alternatives. Additionally, management’s proven acquisition
track record paired with an actionable add-on pipeline present a unique consolidation opportunity
for the Company.

Fund IV partnered with the Company’s founder, Dr. John Hamide, as well as management, to recapitalize
the business and provide additional capital to support the Company’s organic and acquisition
growth initiatives. Dr. Hamide will remain on the Company’s board of directors while retaining a
meaningful equity stake, and the Company’s CEO, John Stagg, will continue to manage the
day-to-day operations of the business.
“We are excited to be working with Dr. Hamide, John Stagg and the entire Capitol Imaging team,”
commented Geoff Faux, Principal of Clearview Capital. “We believe the Company has a tremendous
opportunity to strengthen its density within its existing footprint and expand into new markets
in the Gulf South region.”

“Our team is thrilled to partner with Clearview Capital to accelerate our growth trajectory,”
remarked John Stagg, CEO. “We are excited to have a strong and experienced partner who is as
committed to our success as we are and will help us further build our infrastructure and geographic reach.”
“The partnership with Clearview is a fantastic opportunity to augment the Company’s acquisition strategy,” added Dr. John Hamide. “Clearview
brings the relevant experience in healthcare services, as well as experience executing buy-and-build growth strategies, to allow us to acquire on
a larger scale than ever before.”

Capitol Imaging is the third platform investment in Fund IV, a $550 million committed fund raised in 2018.

Holdings in funds managed by Clearview Capital include Higdon Outdoors, LLC, a designer and supplier of premium-branded hunting and pet
accessories; Workforce Solutions, a provider of management consulting services focused on organizational improvement, leadership development, communications and advocacy for a broad array of clients; Apothecare Pharmacy, LLC, an institutional pharmacy targeting the behavioral health sector; Community Medical Services Holdings, LLC, a provider of medication-assisted treatment programs for patients suffering from substance use disorders; UpSwell, LLC f.k.a Mudlick Mail, LLC, a data-driven direct mail and related marketing solutions provider;
Nielsen-Kellerman Co., a designer and manufacturer of premium environmental and athletic performance measurement instruments; Orchard &
Vineyard Supply f.k.a. Wilson Orchard & Vineyard Supply, a provider of orchard and vineyard supplies and solutions, and outsourced vineyard
management services; Controlled Products, LLC, a manufacturer and distributor of premium quality synthetic turf; Elevation Labs f.k.a. Northwest
Cosmetic Labs, a formulator and manufacturer of cosmetic and skin care products for prestige brands; Derby Building Products, Inc. f.k.a.
Novik, Inc., an innovator, manufacturer and distributor of polymer building products; Child Health Holdings, Inc. d.b.a. Pediatric Health Choice,
the country’s largest operator of prescribed pediatric extended care (“PPEC”) centers for medically complex children; and Pyramid Healthcare,
Inc., a provider of substance use disorder and mental health treatment programs for adults and adolescents.

Ridgemont Equity Partners Acquires Anne Arundel Dermatology

Ridgemont Equity Partners

October 20, 2020

Leading Dermatology Practice in Mid-Atlantic and Southeast to Expand Footprint and Capabilities

Charlotte, NC (October 20, 2020) – Ridgemont Equity Partners, a middle market private equity investor, today announced the acquisition of Anne Arundel Dermatology Management (“AAD” or the “Company”), a leading provider of medical, surgical and cosmetic dermatological services in the Mid-Atlantic and Southeastern states. AAD has approximately 181 providers across 74 clinics in Maryland, Virginia, Tennessee, North Carolina, and Pennsylvania and is seeking expansion into new geographic markets. The management team at AAD and physician-owners invested alongside Ridgemont in the transaction.

“Ridgemont has been close to the team at Anne Arundel Dermatology for over three years,” said Walker Poole, Partner at Ridgemont. “Given the strong clinical reputation, established presence across the Mid-Atlantic and Southeastern regions, and successful history of practice affiliations, we view AAD as a top-tier dermatological service provider in the US and are very pleased to add the Company to our portfolio.”

“Dermatology is a large and growing sector that remains highly fragmented,” said Dan Harknett, Principal at Ridgemont. “AAD has an excellent group of high quality dermatology providers and a proven management team that is capable of leading a much larger platform – we are excited to support this team and share the next step in the Company’s continued growth.”

“We have experienced tremendous growth across the Anne Arundel platform over the past several years and are proud of the team and infrastructure we have built,” said Scott Mahosky, CEO of AAD. “Our new partners at Ridgemont share the same vision of supporting high quality physicians focused on providing quality care while reducing the providers’ administrative burden. We look forward to partnering with Ridgemont to continue these efforts while increasing our presence in existing markets and expanding into new states.”

Financing for the transaction was provided by Twin Brook Capital Partners, Crescent Direct Lending, First Eagle Alternative Credit, Pathway Capital Management, Northwestern Mutual Investment Management Company, and funds and accounts sub-advised by Churchill Asset Management. Dechert LLP provided legal services to Ridgemont. Robert W. Baird & Co. served as financial advisor to Ridgemont and Coker Capital served as financial advisor to Anne Arundel Dermatology. Financial terms of the transaction were not disclosed.


About Anne Arundel Dermatology

Anne Arundel Dermatology is a leading provider of dermatological services in Maryland, Virginia, Tennessee, North Carolina, and Pennsylvania. Headquartered in Linthicum Heights, Maryland and with 74 locations and 181 providers, AAD provides a comprehensive suite of dermatologic services, offering general dermatology, advanced treatment options for skin cancer and cosmetic procedures. www.aadermatology.com.

About Ridgemont Equity Partners

Ridgemont Equity Partners is a Charlotte-based middle market buyout and growth equity investor. Since 1993, the principals of Ridgemont have invested approximately $4.4 billion. The firm focuses on equity investments up to $250 million in industries in which it has deep expertise, including business and industrial services, energy, healthcare, and technology and telecommunications.

Categories: News

Tags:

Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

Frazier Helathcare partners

| Source: Tarsus Pharmaceuticals, Inc

IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $88.0 million, before underwriting discounts, commissions, and offering expenses payable by Tarsus. In addition, Tarsus has granted the underwriters an option for a period of 30 days to purchase up to 825,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Tarsus.

Tarsus’ common stock is expected to begin trading on The Nasdaq Global Select Market on October 16, 2020 under the symbol “TARS.” The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

BofA Securities, Jefferies and Raymond James are acting as joint book-running managers for the offering. LifeSci Capital and Ladenburg Thalmann are acting as co-managers for the offering.

A registration statement relating to the offering of these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on October 15, 2020. Copies of the registration statement can be accessed by visiting the SEC website at www.sec.gov. The securities referred to in this release are to be offered only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the SEC and forms a part of the effective registration statement. When available, a copy of the final prospectus relating to the offering may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Jefferies at 1-877-821-7388 or by email at prospectus_department@jefferies.com; and Raymond James at 1-800-248-8863 or by email at prospectus@raymondjames.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms of the offering or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus that forms a part of the effective registration statement filed with the SEC. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:
Allison Howell
Pascale Communications, LLC
allison@pascalecommunications.com

Categories: News

Tags:

Eurazeo Patrimoine supports C2S GROUP’S expansion with the acquisition of four new clinics

Eurazeo

Paris, 12 October 2020
Eurazeo Patrimoine, the Eurazeo division specialising in real estate and in companies operating their own real assets, has been an investor in C2S Group since March 2018. Currently the eighth-largest operator of private clinics in France, C2S Group today announced that it has stepped up its expansion with the acquisition of four additional clinics in Franche-Comté: the Clinique Saint-Vincent and the Polyclinique de Franche-Comté in Besançon, the Clinique Saint-Pierre in Pontarlier, and the Polyclinique du Parc in Dole.

The integration of these four clinics, all leading facilities in their catchment areas, staffed by teams of recognised professionals and offering complete diagnostic and treatment services, will allow C2S Group to build up a first-rate network of clinics in Franche-Comté.

Since the acquisition of C2S in 2018, Eurazeo Patrimoine has lent its support to the Group as an active shareholder, bringing it the human and financial resources necessary for its growth, thus contributing to a twofold increase in activity in just three years, accompanied by the expansion of its network in south-east central and eastern France. The integration of five new clinics in Auxerre, Vesoul, Grenoble, Dole and Pontarlier, together with two in Besançon, all acquired over a period of less than three years, alongside the 11 facilities already being managed by C2S in 2018 when it was acquired by Eurazeo Patrimoine, has enabled the Group to increase its footprint, bringing it closer to patients and making it the leading operator of multidisciplinary clinics in the Auvergne-Rhône-Alpes and Bourgogne-Franche-Comté regions.

Thanks to the strategic vision shared by the senior executives of both C2S and Eurazeo Patrimoine, the Group has also been able to better align its business model with its values of closeness, quality, balanced medical and managerial governance, and responsible development during this growth phase.
Lastly, Eurazeo Patrimoine’s support for C2S Group has been reflected in major investment programmes: in real estate (expansion and renovation projects, creation of surgical units as well as new out-patient or emergency services) to modernise its clinics and accompany the rise in activity; in medical equipment (acquisition of surgical robots, including the first European CMR robot in operation in France) to provide the facilities and their practitioners with state-of-the-art tools and ensure an excellent standard of care for patients within their communities; and in digital technology, including the digitisation of the patient experience and a strengthened partnership with Doctolib, of which Eurazeo is a main shareholder.

Renaud Haberkorn, Head of Eurazeo Patrimoine, said:
We are very pleased to have supported C2S for nearly three years. With its recent acquisitions, the Group has taken a major step forward in its growth and in the consolidation of its leadership position in its sector at the regional level. Since 2018, Eurazeo Patrimoine’s teams have worked very closely with those at C2S Group. We are proud to be accompanying this preeminent healthcare provider in the Auvergne-Rhône-Alpes and Bourgogne-Franche-Comté regions through every step of its development.

Jean Rigondet, Chairman of C2S Group, said:
The four recently acquired clinics are all leading healthcare facilities for the Franche-Comté area, staffed by teams of talented professionals, working in a coordinated manner and with a collegial spirit, able to offer a full care pathway to patients. We are pleased that these clinics are joining the Group and that we are able to ensure a high standard of care for their communities. We aim to meet the needs of patients by providing them with top-quality healthcare services across a range of disciplines. In line with C2S Group’s continuing growth, our partnership with our shareholder Eurazeo Patrimoine, and the relationship based on attentiveness and mutual trust that we enjoy, are essential to the Group’s development.

About Eurazeo
• Eurazeo is a leading global investment company, with a diversified portfolio of €18.5 billion in assets under management, including €12.9 billion from third parties, invested in over 430 companies. With its considerable private equity, real estate and private debt expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 300 professionals and by offering in-depth sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.

• Eurazeo has offices in Paris, New York, São Paulo, Seoul, Shanghai, London, Luxembourg, Frankfurt, Berlin and Madrid.
• Eurazeo is listed on Euronext Paris.
• ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

EURAZEO CONTACTS

PIERRE BERNARDIN
HEAD OF INVESTOR RELATIONS
Email: pbernardin@eurazeo.com
Tel: +33 (0)1 44 15 16 76

VIRGINIE CHRISTNACHT
HEAD OF COMMUNICATIONS
Email: vchristnacht@eurazeo.com
Tel: +33( 1 44 15 76 44

 

PRESS CONTACT

MAITLAND/amo
DAVID STURKEN
Email: dsturken@maitland .co .uk
Tel: +44 ( 7990 595 913

 

Categories: News

Tags: